

Dedication

To my:

- Beloved and blessed parents Zeinb and Khalid who did everything for me.

Acknowledgment

Primary my praise and thanks should be to Allah, the almighty most gracious and most merciful, who grated me the serenity, means of strength and practice to accomplish this work.

I am deeply indebted to my supervisor Dr: Khalda Mirghani Hamzafor her valuable help and guidance during this study I am also great to his patience assistance and invaluable device.

My appreciation is extend to Dear sisters, brothers,my friends, my aunt ,all academic staff, technologist and other members of the department of haematology Sudan University of science and technology and Al-Gdarif hospital staff.

Abstract

This is an analytical case-control study, conducted at Al- Gdarif Teaching Hospital during the period from January to April 2010. The aim of this study was assessment of the haemostatic parameters (platelet, PT, APTT and TT) and haemoglobin, tests in visceral leishmaniasis patients attended Al-GadarifTeachingHospital.

Fifty visceral leishmaniasis patients were informed about the study and agreed for participation. The study population was divided into two groups according to sex, 5 groups according to age, 15 groups according to tribe.

Five ml of venous blood was bleed 2.5mlin EDTA containers and 2.5 ml in tri sodium citrate containers and investigated for the Hb level, platelet count, PT, APTT and TT tests.

Fully automated haematological analyzer Sysmexwas used for Hb, platelet, and manual analysis for PT, APTT and TT.

All visceral leishmaniasis patients had mean values of Platelet=115.000cell/mm³ decrease significant than control mean value = 198.000cell/mm³,PT=16.4second, prolong significant than control mean value = 14.5 second, P.value = 0.029. INR=1.5, increased but not significant than control mean value = 1.4, P.value = 0.288.APTT=31.8second, prolonged significant than control mean value = 28.3,P.value = 0.001.TT=9.3second, prolonged than control mean value = 9 second but in significant, p. value = 0.46.andHb = 8.4g/dl,decrease significant than control mean value of Hb 13g/dl, P.value = 0.000.

مستخلص الأطروحة

هذه دراسة تحليلية تعتمد على المقارنة بين الحالة والمعيار المفترض تم إجراؤها في الفترة ما بين شهر يناير إلى شهر ابريل ٢٠١٠ بمستشفى القصرين التعليمي لقياس عوامل التجلط ومستوي خضاب الدم بمرضى اللشمانيا الحشوية.

أخذت خمسون عينة من مرضى اللشمانيا الحشوية بعد إخبارهم بهذه الدراسة وأهميتها وأخذ موافقهم على المشاركة.

قسم مرضى اللشمانيا إلى ذكور وإناث في خمسة مجموعات عمرية وخمسة عشر قبيلة وأربعة مجموعات على حسب الجرعات الدوائية، تم اخذ خمسة مل من الدم من كل مشارك في الدراسة وقسمت إلى ٢.٥ مل في حاويات تحتوي على مانع تجلط (EDTA) و ٢.٥ مل في حاويات تحتوي على سترات الصوديوم الثلاثية.

تم استخدام جهاز (Sysmex) لتحليل خضاب الدم والصفائح الدموية والذي يعمل أوتوماتيكياً وتم تحليل زمن البروثرومبين وزمن الثرموبلاستين الجزيئي المنشط وزمن الثرومبين بالطريقة اليدوية. كان لجميع مرضى اللشمانيا الحشوية القيم المتوسطة التالية :

الصفائح الدموية $115.000 \text{ cell/mm}^3$ ، $198.000 \text{ cell/mm}^3$ أظهرت انخفاضاً كبيراً من المعيار بمستوى معنوية = ٠.٠٠٠، زمن البروثرومبين = ١٦.٤ second إطالة كبيرة من قيمة المعيار = ١٤.٥ ثانية بمستوى معنوية = ٠.٠٢٩، INR = ١.٥ زيادة ولكن ليست بكثيره من المعيار = ١.٤ بمستوى معنوية = ٢٨٨.٠، زمن الثرموبلاستين الجزيئي = ٣١.٨ second إطالة كبيرة من قيمة المعيار = ٢٨.٣ second بمستوى معنوية = ٠.٠٠١، زمن الثرومبين = ٩.٣ second إطالة ليست بكثيره من قيمة المعيار ٩ second بمستوى معنوية = ٠.٤٦ . خضاب الدم = ٨.٤ ، انخفاضاً كبيراً من المعيار بمستوى معنوية = ٠.٠٠٠.٠ .

List of abbreviation

| | |
|---------------|--|
| 2,3- DPG | 2,3 di phosphglycerate |
| ADP | Adenosine diphosphate |
| AGM | Aorta-gonads-mesonephros |
| ALA | Aminolevulinic acid |
| APTT | Active Partial thromboplastin time |
| C3, C4, C5 | Complement protein |
| Ca cl | Calcium chloride |
| cAMP | Cyclic adenosine monophosphate |
| CD | Cluster differentiation |
| CFu | Olony forming unit |
| CL | Cutaneous leishmaniasis |
| COA | Co enzyme A |
| DAT | Direct agglutination test |
| DVT | Deep vein thrombosis |
| E PCR | Endothelial PC receptor |
| EDTA | Ethylene diamine tetra acetic acid |
| FDPs | Fibrinogen degradation product |
| GEMM | Granulocyte eosinophil monocyte megakaryocyte |
| GM- CSF | Granulocyte megakaryocyte - colony stimulating factor. |
| Gp | Glycoprotein |
| Hb | Haemoglobin |
| HCT | Haematocrit |
| HGB | Haemoglobin |
| HIV | Human immune virus |
| HMWK | High molecular weight kallikerin |
| IFN- γ | Interferon gamma |
| IgA | Immunoglobulin A |
| IgG | Immunoglobulin G |
| IgM | Immunoglobulin M |
| IL | Interleukin |
| INR | International normalize ratio |
| ISI | International sensitivity index |
| ITP | Idiopathic thrombocytopenic purura |
| MCH | Mean cell haemoglobin |
| MCHC | Mea cell haemoglobin concentration |
| MCL | Muco Cutaneous leishmaniasis |
| MCV | Mean cell volume |

| | |
|------------------|---|
| MPV | Mean platelet volume |
| NO | Nitric oxide |
| PAP | Plamin anti plasmin complex |
| PC | Protein C |
| PE | Pulmonary embolism |
| PPP | Platelet poor plasma |
| PT | Prothrombin time |
| RBCS | Red blood cells |
| RDW | Red cell distribution width |
| TAFI | Thrombin activated fibrinolysis inhibitor |
| TAT | Thrombin anti thrombin |
| TFPI | Tissue factor pathway inhibitor |
| TGF | Trans forming growth factor |
| TNF | Tumor necrosis factor |
| tPA | Tissue plasminogen activator. |
| TT | Thrombin time |
| TXA ₂ | Thromboxane A ₂ |
| TXB ₂ | Thromboxane B ₂ |
| uPA | Urokinaseplasminogen activator |
| VL | Visceral leishmaniasis |
| VWF | Vonwillebrand factor |
| WBCs | White blood cells |

List of tables

| Table No. | Subject | Page No. |
|------------------|--|-----------------|
| Table 3.1 | Statistical comparisons of, coagulation tests and haemoglobin between patient and control. | 48 |
| Table 3.2 | Distribution of patients according to sex. | 49 |
| Table 3.3 | Distribution of patients according to age. | 49 |
| Table 3.4 | Distribution of patients according to Tribe. | 50 |
| Table 3.5 | Distribution of parameter according to sex. | 51 |
| Table 3.6 | Distribution of parameter according to Age .. | 52 |

Contents

| | Subjects | Page No |
|--|--|----------------|
| 1 | Dedication | I |
| 2 | Acknowledgement | II |
| 3 | Abstract English | III |
| 4 | Abstract Arabic | IV |
| 5 | List of abbreviation | V |
| 6 | List of tables | VI |
| 7 | List of Content | VII |
| Chapter one: Introduction and literature review | | |
| 1.1 | Back ground | 1 |
| 1.2 | Site of haemopoiesis | 1 |
| 1.2.1 | Haemopoietic stem and progenitor cell | 2 |
| 1.2.2 | Bone marrow stroma | 3 |
| 1.2.3 | Haemopoietic growth factors | 3 |
| 1.3 | Haemesynthesis and hemoglobin | 4 |
| 1.4 | Normal haemeostasis | 5 |
| 1.4.1 | Components normal homeostasis | 6 |
| 1.4.1.1 | Blood Vessel | 6 |
| 1.4.1.1.1 | The General Structure of the Blood Vessel | 6 |
| 1.4.1.1.2 | Endothelial Cell Function | 7 |
| 1.4.1.1.3 | Vasoconstriction | 8 |
| 1.4.1.2 | Platelets | 9 |
| 1.4.1.2.1 | Platelet Function in the Haemostatic Process | 9 |
| 1.4.1.2.2 | Platelet Aggregation | 10 |
| 1.4.1.3 | Coagulation factors | 12 |
| 1.4.1.3.1 | Physiological Coagulation (In Vivo) | 12 |
| 1.4.1.3.2 | Laboratory Model of Coagulation | 13 |
| 1.4.1.3.3 | Extrinsic Pathway | 13 |
| 1.4.1.3.3.1 | Prothrombin time | 13 |
| 1.4.1.3.4 | Intrinsic System | 14 |
| 1.4.1.3.4.1 | Activated Partial Thromboplastin Time | 14 |
| 1.4.1.3.5 | Common Pathway | 15 |

| | | |
|----------------|--|----|
| 1.4.1.3.6 | The Contact Activation System | 15 |
| 1.4.1.3.7 | Tissue Factor | 16 |
| 1.4.1.3.8 | The Vitamin K–Dependent Factors | 16 |
| 1.4.1.3.9 | Cofactors | 17 |
| 1.4.1.3.10 | Fibrinogen | 17 |
| 1.4.1.3.11 | Factor XIII | 18 |
| 1.4.1.3.12 | Inhibitors of Coagulation | 18 |
| 1.4.1.3.13 | The Fibrinolytic System | 19 |
| 1.4.1.3.14 | Vascular Defects | 21 |
| 1.4.1.3.14.1 | Henoch-Schönleinpurpura | 21 |
| 1.4.1.3.14.2 | Hereditary hemorrhagic telangiectasia | 21 |
| 1.4.1.3.15 | Abnormalities of Platelets | 21 |
| 1.4.1.3.15.1 | Idiopathic Thrombocytopenic Purpura | 22 |
| 1.4.1.3.15.2 | Incidence & Etiology | 22 |
| 1.4.1.3.15.3 | Pathology of platelet | 22 |
| 1.4.1.3.15.4 | Abnormalities of Platelet Function | 23 |
| 1.4.1.3.16 | Disorders of Blood Coagulation | 23 |
| 1.4.1.3.16.1 | Etiology | 23 |
| 1.4.1.3.16.2 | Deficiency of Coagulation Factors | 23 |
| 1.4.1.3.16.3 | Fibrinolytic Activity | 24 |
| 1.4.1.3.16.4 | Factor VIII Deficiency | 24 |
| 1.4.1.3.16.5 | Hemophilia A | 24 |
| 1.4.1.3.16.5.1 | Incidence & Etiology of Hemophilia A | 24 |
| 1.4.1.3.16.5.2 | Pathology & Clinical Features | 25 |
| 1.4.1.3.16.5.3 | Spontaneous bleeding | 25 |
| 1.4.1.3.16.6 | Von Willebrand's Disease | 26 |
| 1.4.1.3.16.7 | Factor IX Deficiency (Christmas Disease; Hemophilia B) | 26 |
| 1.4.1.3.16.8 | Disseminated Intravascular Coagulation & Fibrinolysis | 27 |
| 1.5 | Leishmaniasis | 27 |
| 1.5.1 | Morphology of leishmania parasite | 28 |
| 1.5.2 | Transmission and life cycle | 28 |
| 1.5.3 | Sandfly vectors | 28 |
| 1.5.4 | Pathogenesis of leishmania | 29 |
| 1.5.5 | Classification of Leishmaniasis | 29 |
| 1.5.5.1 | Cutaneous leishmaniasis (CL) | 29 |
| 1.5.5.2 | Old world CL | 29 |

| | | |
|-------------|--|----|
| 1.5.5.3 | New world CL | 30 |
| 1.5.5.4 | Mucocutaneous leishmaniasis (MCL) | 31 |
| 1.5.5.5 | Visceral leishmaniasis (VL) | 31 |
| 1.5.5.6 | Post kala-azar dermal leishmaniasis (PKDL) | 32 |
| 1.5.5.7 | Leishmaniasis and HIV infection | 32 |
| 1.5.6 | Laboratory diagnosis of leishmaniasis | 33 |
| 1.5.6.1 | Diagnosis of cutaneous and mucocutaneous leishmaniasis | 33 |
| 1.5.6.1.1 | Serological diagnosis of CL and MCL | 33 |
| 1.5.6.1.2 | Collection and examination of slit skin smears for amastigotes | 33 |
| 1.5.6.1.3 | Culture of ulcer material | 33 |
| 1.5.6.1.4 | Leishmanin skin test | 33 |
| 1.5.61.4.1 | Positive reaction | 34 |
| 1.5.61.4.2 | Negative reaction | 34 |
| 1.5.6.2 | Diagnosis of visceral leishmaniasis | 34 |
| 1.5.6.2.1 | Examination of buffy coat preparations for amastigotes | 34 |
| 1.5.6.2.2 | Examination of aspirates for amastigotes | 35 |
| 1.5.6.2.2.1 | Splenic aspiration | 35 |
| 1.5.6.2.3 | Detection of anti-leishmanial antibody | 35 |
| 1.5.6.2.3.1 | Direct agglutination test | 35 |
| 1.5.6.2.3.2 | rK39 dipstick to detect anti-rK39 antibody | 36 |
| 1.5.6.2.4 | Formol gel (aldehyde) test | 37 |
| 1.6 | Rationale | 38 |
| 1.7 | Objectives | 39 |
| 1.7.1 | General objective | 39 |
| 1.7.2 | Specific objective | 39 |

Chapter Two: Material and method

| | | |
|------|-----------------------|----|
| 2.1 | Study design | 40 |
| 2.2 | Study area | 40 |
| 2.3 | Study population | 40 |
| 2.4 | Sample size | 40 |
| 2.5 | Inclusion criteria | 40 |
| 2.6 | Exclusion criteria | 40 |
| 2.7 | Data collection | 40 |
| 2.8 | Data analysis | 40 |
| 2.9 | Ethical consideration | 40 |
| 2.10 | Time line | 41 |

| | | |
|---|---------------------------------------|----|
| 2.11 | Methodology | 41 |
| 2.11.1 | Collection technique | 41 |
| 2.11.1.1 | Requirements | 41 |
| 2.11.1.2 | Procedure | 41 |
| 2.11.2 | Platelet count | 42 |
| 2.11.3 | Prothrombin Time | 42 |
| 2.11.3.1 | Principle | 42 |
| 2.11.3.2 | Reagents | 42 |
| 2.11.3.3 | Patient and Control Plasma Samples | 42 |
| 2.11.3.4 | Preparation of Platelet Poor Plasma | 42 |
| 2.11.3.5 | Thromboplastin | 43 |
| 2.11.3.6 | Method | 43 |
| 2.11.3.7 | Expression of Results | 43 |
| 2.11.3.8 | Normal Values | 44 |
| 2.11.4 | Activated Partial Thromboplastin Time | 44 |
| 2.11.4.1 | Principle | 44 |
| 2.11.4.2 | Reagent | 44 |
| 2.11.4.3 | Kaolin | 44 |
| 2.11.4.5 | Phospholipid | 45 |
| 2.11.4.6 | Method | 45 |
| 2.11.4.7 | Normal Range | 45 |
| 2.11.5 | Thrombin Time | 45 |
| 2.11.5.1 | Principle | 45 |
| 2.11.5.2 | Reagents | 46 |
| 2.11.5.3 | Thrombin solution | 46 |
| 2.11.5.4 | Method | 46 |
| 2.11.5.5 | Expression of Results | 46 |
| 2.11.5.6 | Normal Range | 46 |
| Chapter three: Result | | |
| 3. | Result | 47 |
| Chapter four: Discussion, Conclusion, Recommendation | | |
| 4.1 | Discussion | 53 |
| 4.2 | Conclusion | 55 |
| 4.3 | Recommendation | 56 |
| References | | |
| Appendices | | |